Cardiac risks with COX-2 inhibitors.
Ashworth
Andrew J
AJ
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000453:epidemiology; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D010003:Osteoarthritis / Q000188:drug therapy; D012307:Risk Factors; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use; D013997:Time Factors
D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib